Friday 6 November 2026
Export WGS’s income statement to Excel — free account
GeneDx Holdings Corp.
WGS Healthcare Diagnostics & Research
GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- −257.9%
- Free cash flow
- −585.6%
- Total debt
- +87.4%
Quarter to June 2026, against a year earlier
62.46
1.90
−2.95%
Follow WGS
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 3 | 6 | 8 |
+8 more TTM periods Free account |
| (40.80%) | (30.42%) | (7.60%) | 0.84% | ||
| (22.50%) | (16.33%) | (4.46%) | 0.46% | ||
ROIC |
(27.70%) | (22.89%) | (4.42%) | 3.30% | |
Return on Tangible Assets |
(47.05%) | (33.38%) | (10.25%) | 1.08% | |
Average Days of Receivables |
67.16 | 63.43 | 63.49 | 55.30 | |
Free Cash Flow per Share |
(2.55) | (0.98) | 0.50 | 0.54 | |
Free Cash Flow |
(75.80) | (28.65) | 14.26 | 15.47 | |
Capital Expenditures |
(27.09) | (19.34) | (19.02) | (17.72) | |
| Other line items | |||||
Cash ROIC |
(16.00%) | (5.49%) | 2.70% | 3.10% | |
Accounts Receivable Turnover |
6.90 | 7.20 | 7.63 | 8.09 | |
Accounts Payable Turnover |
3.05 | 3.05 | 2.92 | 2.29 | |
Inventory Turnover |
9.36 | 10.82 | 10.52 | 11.44 | |
Average Days of Payables |
110.38 | 126.10 | 162.64 | 150.49 | |
Days of Inventory on Hand |
46.73 | 33.15 | 39.36 | 31.60 | |
Tax Rate |
0.00 | 0.00 | (0.01) | (0.17) | |
Research and Development Expense of Revenue |
18.45% | 17.90% | 16.85% | 14.69% | |
Selling, General and Administrative Expense of Revenue |
64.38% | 59.49% | 55.95% | 52.48% | |
Share Based Compensation of Revenue |
7.86% | 8.40% | 7.52% | 6.27% | |
Interest Coverage |
(28.17) | (24.12) | — | 3.48 | |
Operating CF/Net income |
0.46 | 0.12 | (1.58) | 15.93 | |
Depreciation/Fixed assets |
0.49 | 0.53 | 0.55 | 0.56 | |
Capex/Depreciation |
(1.01) | (0.73) | (0.75) | (0.74) | |
Revenue per Share |
15.30 | 15.09 | 14.93 | 13.97 | |
Operating CF per Share |
(1.64) | (0.32) | 1.16 | 1.15 | |
Capex per Share |
(0.91) | (0.66) | (0.66) | (0.62) | |
Capex to Sales |
0.06 | 0.04 | 0.04 | 0.04 |
Columns are period end dates · fundamentals updated 26 Oct 2026